Raiffeisen Bank International AG Has $10.22 Million Position in Boston Scientific Corporation $BSX

Raiffeisen Bank International AG boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 5.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,948 shares of the medical equipment provider’s stock after buying an additional 5,384 shares during the quarter. Raiffeisen Bank International AG’s holdings in Boston Scientific were worth $10,215,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. 1248 Management LLC bought a new position in shares of Boston Scientific during the first quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the first quarter valued at $27,000. Sound Income Strategies LLC raised its position in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the last quarter. Princeton Global Asset Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $37,000. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Raymond James Financial raised their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. BTIG Research reissued a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research report on Wednesday, October 22nd. Barclays boosted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Stock Down 1.0%

Boston Scientific stock opened at $101.71 on Tuesday. The company has a market capitalization of $150.78 billion, a PE ratio of 54.39, a PEG ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The firm’s fifty day moving average is $99.59 and its 200 day moving average is $102.55. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period last year, the company posted $0.63 earnings per share. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,782 shares of company stock valued at $17,742,314 over the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.